B

BioPlus Co Ltd
KOSDAQ:099430

Watchlist Manager
BioPlus Co Ltd
KOSDAQ:099430
Watchlist
Price: 7 090 KRW Market Closed
Market Cap: 428.9B KRW
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

Price Targets Summary
BioPlus Co Ltd

Wall Street analysts forecast BioPlus Co Ltd stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BioPlus Co Ltd is 9 945 KRW with a low forecast of 9 595 KRW and a high forecast of 10 500 KRW.

Lowest Forecast
Wall Street Target
9 595 KRW
35% Upside
Average Forecast
Wall Street Target
9 945 KRW
40% Upside
Highest Forecast
Wall Street Target
10 500 KRW
48% Upside
Lowest
Price Target
9 595 KRW
35% Upside
Average
Price Target
9 945 KRW
40% Upside
Highest
Price Target
10 500 KRW
48% Upside
BioPlus Co Ltd Competitors:
Price Targets
SDI
SDI Ltd
55% Upside
PNV
Polynovo Ltd
91% Upside
V
6782
Visco Vision Inc
37% Upside
XVIVO
Xvivo Perfusion AB
131% Upside
SDI
SDI Ltd
55% Upside
PNV
Polynovo Ltd
91% Upside
V
6782
Visco Vision Inc
37% Upside
XVIVO
Xvivo Perfusion AB
131% Upside
BLFS
BioLife Solutions Inc
45% Upside
300981
Zhonghong Pulin Medical Products Co Ltd
4% Downside
V
VIMIAN
Vimian Group AB
17% Upside
RMTI
Rockwell Medical Inc
264% Upside

Revenue
Forecast

Revenue Estimate
BioPlus Co Ltd

For the last 5 years the compound annual growth rate for BioPlus Co Ltd's revenue is 31%. The projected CAGR for the next 3 years is 33%.

31%
Past Growth
33%
Estimated Growth
Estimates Accuracy
0%
Average Beat
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
BioPlus Co Ltd

For the last 5 years the compound annual growth rate for BioPlus Co Ltd's operating income is 28%. The projected CAGR for the next 3 years is 38%.

28%
Past Growth
38%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
BioPlus Co Ltd

For the last 5 years the compound annual growth rate for BioPlus Co Ltd's net income is 20%. The projected CAGR for the next 2 years is 67%.

20%
Past Growth
67%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BioPlus Co Ltd's stock price target?
Price Target
9 945 KRW

According to Wall Street analysts, the average 1-year price target for BioPlus Co Ltd is 9 945 KRW with a low forecast of 9 595 KRW and a high forecast of 10 500 KRW.

What is BioPlus Co Ltd's Revenue forecast?
Projected CAGR
33%

For the last 5 years the compound annual growth rate for BioPlus Co Ltd's revenue is 31%. The projected CAGR for the next 3 years is 33%.

What is BioPlus Co Ltd's Operating Income forecast?
Projected CAGR
38%

For the last 5 years the compound annual growth rate for BioPlus Co Ltd's operating income is 28%. The projected CAGR for the next 3 years is 38%.

What is BioPlus Co Ltd's Net Income forecast?
Projected CAGR
67%

For the last 5 years the compound annual growth rate for BioPlus Co Ltd's net income is 20%. The projected CAGR for the next 2 years is 67%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 267,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.